Inventory

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Inventory

(4) Inventory

The Company capitalizes its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories as of March 31, 2020 and December 31, 2019 consist of the following:

In thousands	March 31, 2020		December 31, 2019
Raw materials		18,771	$	19,455
Work in process		22,006		12,031
Finished goods		51,344		45,283
Total inventory	$	92,121	$	76,769